OncoMatch/Clinical Trials/NCT07126236
Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma
Is NCT07126236 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Epcoritamab and Epcoritamab, tafasitamab and lenalidomide for large b cell lymphoma.
Treatment: Epcoritamab · Epcoritamab, tafasitamab and lenalidomide — phase II, response-adaptive, open-label, multicenter study aiming to include 80 patients in 78 months. Patients will receive 3 cycles of epcoritamab monotherapy and, since cycle 4, they can continue with epcoritamab monotherapy until cycle 12 or change to combination therapy (epcoritamab + tafasitamab + lenalidomide) until cycle 15. Patients will be followed up to 5 years.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 monoclonal antibody (rituximab, obinutuzumab) — first-line
Patients must have received adequate first-line therapy including at a minimum: an anti-CD20 monoclonal antibody (rituximab or obinutuzumab), and CHOP (cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone) or CHOP-like chemotherapy.
Must have received: cytotoxic chemotherapy (CHOP, CHOP-like) — first-line
Patients must have received adequate first-line therapy including at a minimum: an anti-CD20 monoclonal antibody (rituximab or obinutuzumab), and CHOP (cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone) or CHOP-like chemotherapy.
Cannot have received: autologous stem cell transplant
Previous ASCT
Cannot have received: anti-CD3 and CD20 bispecific antibodies
Prior anti-CD3 and CD20 bispecific antibodies therapy
Cannot have received: anti-CD19 monoclonal antibody (tafasitamab)
prior treatment with tafasitamab
Cannot have received: CAR-T cell therapy
Exception: unless not a candidate or unwilling
patient should not be a candidate for 1st relapse CAR-T therapy or unwilling to receive CAR-T therapy
Lab requirements
Blood counts
Hemoglobin ≥8 g/dl (transfusion support permitted but not within 7 days of screening lab collection); ANC ≥ 1/109/L (growth factor support allowed in case of bone marrow involvement); Absolute lymphocyte count ≥ 0.1/109/L; Platelet count ≥ 70/109/L (unless secondary to bone marrow involvement, OR ≥50x/109/L if documented bone marrow involvement). Platelet transfusions permitted but not within 7 days of screening lab collection.
Kidney function
creatinine clearance calculated by Cockcroft-Gault > 45 ml/min
Liver function
direct bilirubin level < 2 x ULN (except in patients with Gilbert's syndrome), ALT and AST ≤ 3 × ULN or ≤ 5 × ULN in cases of documented liver involvement
Cardiac function
left ventricular ejection fraction (LVEF) > 45%
creatinine clearance calculated by Cockcroft-Gault ≤ 45 ml/min [excluded]; direct bilirubin level < 2 x ULN (except in patients with Gilbert's syndrome), ALT and AST ≤ 3 × ULN or ≤ 5 × ULN in cases of documented liver involvement; Hemoglobin ≥8 g/dl...; LVEF > 45%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07126236 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous stem cell transplant, anti-CD3 and CD20 bispecific antibodies, anti-CD19 monoclonal antibody disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify